FGFR4 and prostate carcinoma: In addition, when concerning tumor stage and FGFR4 Gly388Arg polymorphism, patients with prostate cancer with Arg/Arg genotype had a 1.34-fold increased risk of advanced or metastatic prostate cancer (95% CI: 1.03-1.74) compared with the Gly/Gly+Gly/Arg genotype (seen Figure 2).